NCT06668584 is a Phase 2 clinical trial of Olutasidenib in Myeloid Malignancies, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT06668584?

NCT06668584 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT06668584?

Interventions in NCT06668584: Olutasidenib.

What condition does NCT06668584 study?

NCT06668584 studies Myeloid Malignancies.

Is NCT06668584 still recruiting?

NCT06668584 is currently recruiting now. Last updated 4 March 2026.

Last reviewed 2026-03-04 · How we verify

NCT06668584

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies

Recruiting now Phase 2 Last updated 4 March 2026

What this trial tests

Phase 2 trial testing Olutasidenib in Myeloid Malignancies in 31 participants. Currently enrolling.

Timeline

31 December 2024

Primary endpoint
31 December 2027

31 December 2029

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	31
Start date	31 December 2024
Primary completion	31 December 2027
Estimated completion	31 December 2029
Sites	1 location across United States

Drugs / interventions tested

Olutasidenib (OLUTASIDENIB) — full drug profile →

Conditions studied

Myeloid Malignancies — all drugs for Myeloid Malignancies →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Adults 18 to 75, any sex, with Myeloid Malignancies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to learn about the safety and tolerability of giving olutasidenib to patients with IDH1-mutated myeloid malignancies as maintenance therapy after they receive a stem cell transplant.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort.
Cortes J, Curti A, Fenaux P, Jonas BA, et al · · 2025 · cited 2× · PMID 41239466 · DOI 10.1186/s13045-025-01751-w

Verify or expand the search:

Other trials of Olutasidenib

Trials testing the same drug.

NCT07411586 — Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia · Phase 1 · not yet recruiting
NCT07153497 — Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-R · Phase 2 · not yet recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
NCT07486713 — Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies · Phase 4 · recruiting
NCT07304011 — Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leuke · Phase 2 · recruiting

Other recruiting trials for Myeloid Malignancies

Currently open trials in the same condition.

NCT07396480 — Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic He · Phase 3 · recruiting
NCT06930651 — A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Kn · Phase 1, PHASE2 · recruiting
NCT06383572 — Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Che · Phase 1, PHASE2 · recruiting
NCT05796570 — A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combine · Phase 2 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06668584 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 4 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06668584.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing